Skip to content
Search

Latest Stories

UK Covid-19 prevalence up due to Delta not Omicron

The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron.

The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were genetically compatible with the Delta variant.


"To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said.

Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to understand it better.

There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.

But it is the spread of the dominant and highly transmissible Delta variant, especially among children, that is keeping infection levels high. On Thursday, Britain reported its highest daily infection number since July.

The ONS said that infections had increased in younger children, with 4.25 per cent estimated to be infected, and remained high in older children, where 3.46 per cent were estimated to be infected.

Ravi Gupta, professor of clinical microbiology, University of Cambridge, said that it was not a given that Omicron would entirely displace Delta, which might continue to circulate in unvaccinated populations like young children.

"More Delta circulating in kids and then more Omicron circulating proportionately in vaccinated individuals is one scenario that could play out... it will be hard to displace Delta completely," he told Reuters.

"Omicron is not spreading rapidly at the moment, by the look of it... there is probably sustained community transmission, but it's probably just starting."

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less